Perrigo Company plc
$12.04
▼
-1.36%
2026-04-21 08:56:01
www.perrigo.com
NYQ: PRGO
Explore Perrigo Company plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.66 B
Current Price
$12.04
52W High / Low
$28.43 / $9.22
Stock P/E
—
Book Value
$21.33
Dividend Yield
9.63%
ROCE
4.16%
ROE
-38.66%
Face Value
—
EPS
$-10.12
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8,100
Beta
0.49
Debt / Equity
131.16
Current Ratio
2.76
Quick Ratio
1.63
Forward P/E
4.55
Price / Sales
0.35
Enterprise Value
$4.81 B
EV / EBITDA
7.08
EV / Revenue
1.13
Rating
Buy
Target Price
$17
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
- Meaningful dividend yield is available.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Hims & Hers Health, Inc. | $28.91 | 56.32 | $6.55 B | — | 6.03% | 25.23% | $70.43 / $13.74 | $2.38 |
| 2. | Aytu BioPharma, Inc. | $2.58 | — | $27.69 M | — | 4.15% | -1.09% | $3.06 / $0.98 | $1.32 |
| 3. | Organigram Global Inc. | $1.51 | 15.08 | $274.04 M | — | -3.51% | 4.64% | $3.09 / $1.37 | $1.97 |
| 4. | BioAge Labs, Inc. | $18.8 | — | $820.58 M | — | -33.77% | -27.09% | $24 / $3.63 | $7.28 |
| 5. | Incannex Healthcare Inc. | $3.84 | — | $51 M | — | — | -1.3% | $49.8 / $2.4 | $6.13 |
| 6. | Lifecore Biomedical, Inc. | $5.35 | — | $200.6 M | — | -5.74% | -612.08% | $8.98 / $3.62 | $-0.38 |
| 7. | Bausch Health Companies Inc. | $5.91 | 14.05 | $3.02 B | — | 9.85% | 4.36% | $11.97 / $6.06 | $-1.5 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.11 B | 1.04 B | 1.06 B | 1.04 B | 1.14 B | — |
| Operating Profit | 84.4 M | 93.4 M | 55.6 M | 79.4 M | 164.8 M | — |
| Net Profit | -1.42 B | 7.5 M | -8.4 M | -6.4 M | -44.5 M | — |
| EPS in Rs | -10.3 | 0.05 | -0.06 | -0.05 | -0.32 | -0.15 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.25 B | 4.37 B | 4.66 B | 4.45 B |
| Operating Profit | 312.8 M | 311.9 M | 284.1 M | 121.4 M |
| Net Profit | -1.43 B | -171.8 M | -12.7 M | -140.6 M |
| EPS in Rs | -10.36 | -1.25 | -0.09 | -1.02 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.54 B | 9.65 B | 10.81 B | 11.02 B |
| Total Liabilities | 5.6 B | 5.33 B | 6.04 B | 6.18 B |
| Equity | 2.94 B | 4.32 B | 4.77 B | 4.84 B |
| Current Assets | 2.8 B | 2.48 B | 2.83 B | 2.72 B |
| Current Liabilities | 1.01 B | 1.04 B | 1.59 B | 1.11 B |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 238.5 M | 362.9 M | 405.5 M | 307.3 M |
| Investing CF | -75.4 M | 78.8 M | -77.5 M | -1.96 B |
| Financing CF | -220.5 M | -611 M | -187.2 M | 421.6 M |
| Free CF | 145.1 M | 244.6 M | 303.8 M | 210.9 M |
| Capex | -93.4 M | -118.3 M | -101.7 M | -96.4 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -6.06% | 4.58% | — | — |
| Earnings Growth % | -1252.76% | 90.97% | — | — |
| Profit Margin % | -3.93% | -0.27% | -3.16% | — |
| Operating Margin % | 7.13% | 6.1% | 2.73% | — |
| Gross Margin % | 35.27% | 36.09% | 32.69% | — |
| EBITDA Margin % | 9.9% | 11.28% | 7.99% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
| Ex Date | Dividend |
|---|---|
| 2026-03-02 | $0.29 |
| 2025-08-29 | $0.29 |
| 2025-05-30 | $0.29 |
| 2025-03-07 | $0.29 |
| 2024-11-29 | $0.276 |
Stock Splits
No stock split history available.